BeiGene Ltd (BGNE)
$184.38 -$2.50 (-1.33%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$22.92B -
Day's Range
$183.26 - $187.64 -
Volume
522,900 -
52 Week Low / High
$126.97 - $248.16 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 13
- Strong Buy
- 7
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $292.53
- Target Price
Company News
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2% — Sep 27th, 2024
With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these ...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2% — Sep 27th, 2024
With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these ...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2% — Sep 27th, 2024
With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these ...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 — Oct 10th, 2024
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally i...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? — Oct 7th, 2024
BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks. The sudden rise in the stock price can...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
-
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years — Oct 17th, 2024
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But BeiGene, Ltd. (NASDAQ:BGNE) has fallen short of that second goal, with a share price rise of 60% over five years, which is...
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 — Oct 16th, 2024
Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ...
-
Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRAin combination with platinum- and fluoropyrimidine-based chemotherapy Positive opin...
Portfolio
Comprised of 1 portfolios